@article{4776,
  keywords = {GBM, GBM-on-a-chip, disease modeling, Drug screening, Tumor Microenvironment},
  author = {Surjendu Maity and Tamanna Bhuyan and Christopher Jewell and Satoru Kawakita and Saurabh Sharma and Huu Tuan Nguyen and Alireza Hassani Najafabadi and Menekse Ermis and Natashya Falcone and Junjie Chen and Kalpana Mandal and Danial Khorsandi and Can Yilgor and Auveen Choroomi and Emily Torres and Marvin Mecwan and Johnson V. John and Mohsen Akbari and Zhaohui Wang and Diogo Moniz-Garcia and Alfredo Quiñones-Hinojosa and Vadim Jucaud and Mehmet Remzi Dokmeci and Ali Khademhosseini},
  title = {Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications},
  abstract = {Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood-brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ-on-a-chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM-on-a-chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM-on-a-chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM-on-a-chip models.},
  journal = {Small},
  volume = {n/a},
  pages = {2405511},
  issn = {1613-6829},
  url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202405511},
  doi = {10.1002/smll.202405511},
  language = {en},
}